Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue

Urology

Volumn 56, Issue 3, 2000, Pages 527-532

  Magklara, Angeliki ^a,b,c   Scorilas, Andreas ^a,b,c   Stephan, Carsten ^c   Kristiansen, Glen O ^c   Hauptmann, Steffen ^c   Jung, Klaus ^c   Diamandis, Eleftherios P ^d  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUANTITATIVE ASSAY;

AGED; DOWN-REGULATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TISSUE KALLIKREINS;

EID: 0033827219     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)00621-X     Document Type: Article

References (29)

1. Diamandis E.P. Prostate-specific antigen - its usefulness in clinical medicine. Trends Endocrinol Metab. 9:1998;310-316.
2. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease a prospective multicenter clinical trial . JAMA. 279:1998;1542-1547.
3. Hakalahti L., Vihko P., Hentty P., et al. Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using Northern blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies. Int J Cancer. 55:1993;590-597.
4. Gallee M.P., Visse de Jong E., van der Korput J.A., et al. Variation of prostate specific antigen expression in different tumour growth patterns present in prostatectomy specimens. Urol Res. 18:1990;181-187.
5. Pretlow T.G., Pretlow T.P., Yang P., et al. Tissue concentrations of prostate specific antigen in prostatic carcinoma and benign prostatic hyperplasia. Int J Cancer. 49:1991;645-649.
6. Henttu P., Lukkarinen O., Vihko P. Expression of the gene coding for human prostate specific antigen and related hGK-1 in benign and malignant tumors of the human prostate. Int J Cancer. 45:1990;654-660.
7. Qiu S.-D., Young C.Y.-F., Bilhartz D.L., et al. In situ hybridization of prostate specific antigen mRNA in human prostate. J Urol. 144:1990;1550-1556.
8. Stege R., Grande M., Carlstrom K., et al. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin Cancer Res. 6:2000;160-165.
9. Rittenhouse H.G., Finlay J.A., Mikolajczyk S.D., et al. Human kallikrein 2 (hK2) and prostate-specific antigen (PSA) two closely related, but distinct, kallikreins in the prostate . Crit Rev Clin Lab Sci. 35:1998;275-368.
10. Diamandis E.P., Yousef G.M., Luo L.Y., et al. The human kallikrein gene family - in carcinogenesis. Trends Endocrinol Metab. 11:2000;54-60.
11. Lovgren J., Rajakoski K., Karp M., et al. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun. 238:1997;549-555.
12. Kumar A., Mikolajczyk S.D., Goel A.S., et al. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res. 57:1997;3111-3114.
13. Takayama T.K., Fujikawa K., Davie E.W. Characterization of the precursor of prostate-specific antigen activation by trypsin and by human glandular kallikrein . J Biol Chem. 272:1997;21582-21588.
14. Kwiatkowski M.K., Recker F., Piironen T., et al. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. Urology. 52:1998;360-365.
15. Magklara A., Scorilas A., Catalona W.J., et al. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem. 45:1999;1960-1966.
16. Darson M.F., Pacelli A., Roche P., et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma a novel prostate cancer marker . Urology. 49:1997;857-862.
17. Darson M.F., Pacelli A., Roche P., et al. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology. 53:1999;939-944.
18. Meyer A., Jung K., Lein M., et al. Factors influencing the ratio of free to total prostate-specific antigen in serum. Int J Cancer. 74:1997;630-636.
19. Jung K., Brux B., Lein M., et al. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue biochemical and diagnostic implications . Clin Chem. 46:2000;47-54.
20. Ferguson R.A., Yu H., Kalyvas M., et al. Ultrasensitive detection of prostate specific antigen by a time-resolved immunofluorometric assay and the Immulite Immunochemiluminescent third generation assay potential applications in prostate and breast cancers . Clin Chem. 42:1996;675-684.
21. Black M.H., Magklara A., Obiezu C., et al. Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross reactivity from prostate specific antigen. Clin Chem. 45:1999;790-799.
22. Fortier A.H., Nelson B.J., Grella D.K., et al. Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst. 91:1999;1635-1640.
23. Heidtmann H.H., Nettelbeck D.M., Mingels A., et al. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br J Cancer. 81:1999;1269-1273.
24. Klee G.G., Goodmanson M.K., Jacobsen S.J., et al. Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2. Clin Chem. 45:1999;800-806.
25. Piironen T., Lovgren J., Karp M., et al. Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. Clin Chem. 42:1996;1034-1041.
26. Black M.H., Magklara A., Obiezu C., et al. Expression of a prostate associated protein, human glandular kallikrein (hK2) in breast tumors and in normal breast secretions. Br J Cancer. 82:2000;361-367.
27. Hsieh M.L., Charlesworth C., Goodmanson M., et al. Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D. Cancer Res. 57:1997;2651-2656.
28. Magklara A., Grass L., Diamandis E.P. Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate specific antigen (PSA) in breast cancer cell lines. Breast Cancer Res Treat. 59:2000;263-270.
29. Nam R.K., Diamandis E.P., Toi A., et al. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate specific antigen. J Clin Oncol. 18:2000;1036-1042.